Belite Bio Non-GAAP EPS of -$0.60 beats by $0.17
at seekingalpha.com (Thu, 12-Nov 3:55 PM)
Belite Bio Reports Third-Quarter Results and Tinlarebant Regulatory Progress
at www.tipranks.com (Thu, 12-Nov 7:14 AM)
Belite Bio moves up to Nasdaq’s top tier as it targets a potential first-ever Stargardt therapy
Market Chameleon (Tue, 20-Oct 11:59 AM)
